|
1
|
Tiseo M, Bartolotti M, Gelsomino F and
Ardizzoni A: First-line treatment in advanced non-small-cell lung
cancer: The emerging role of the histologic subtype. Expert Rev
Anticancer Ther. 9:425–435. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hou S, Han X and Ji H: Squamous transition
of lung adenocarcinoma and drug resistance. Trends Cancer.
2:463–466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loi M, Roche N and Alifano M: Chemotherapy
regimens for non-small cell lung cancer. Minerva Chir. 64:629–641.
2009.PubMed/NCBI
|
|
4
|
Sangodkar J, Katz S, Melville H and Narla
G: Lung adenocarcinoma: Lessons in translation from bench to
bedside. Mt Sinai J Med. 77:597–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tran TH, Dolecek C, Pham PM, Nguyen TD,
Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ and
Farrar J: Dihydroartemisinin-piperaquine against
multidrug-resistant Plasmodium falciparum malaria in Vietnam:
Randomised clinical trial. Lancet. 363:18–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen T, Li M, Zhang R and Wang H:
Dihydroartemisinin induces apoptosis and sensitizes human ovarian
cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ,
Lin LP and Ding J: Dihydroartemisinin induces apoptosis in HL-60
leukemia cells dependent of iron and p38 mitogen-activated protein
kinase activation but independent of reactive oxygen species.
Cancer Biol Ther. 7:1017–1023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q,
Zuo G, Zhou L, Weng Y, Tang M, et al: Dihydroartemisinin inhibits
tumor growth of human osteosarcoma cells by suppressing
Wnt/β-catenin signaling. Oncol Rep. 30:1723–1730. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao C, Gao W and Chen T: Synergistic
induction of apoptosis in A549 cells by dihydroartemisinin and
gemcitabine. Apoptosis. 19:668–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng X, Li L, Jiang H, Jiang K, Jin Y and
Zheng J: Dihydroartemisinin potentiates the anticancer effect of
cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer
cells: Involvement of apoptosis and autophagy. Biochem Biophys Res
Commun. 444:376–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown MD and Sacks DB: Protein scaffolds
in MAP kinase signalling. Cell Signal. 21:462–469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rana A, Rana B, Mishra R, Sondarva G,
Rangasamy V, Das S, Viswakarma N and Kanthasamy A: Mixed lineage
kinase-c-Jun N-yerminal kinase axis: A potential therapeutic target
in cancer. Genes Cancer. 4:334–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fischer S, Koeberle SC and Laufer SA: p38
mitogen-activated protein kinase inhibitors, a patent review
(2005–2011). Expert Opin Ther Pat. 21:1843–1866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zechner D, Craig R, Hanford DS, McDonough
PM, Sabbadini RA and Glembotski CC: MKK6 activates myocardial cell
NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein
kinase-dependent manner. J Biol Chem. 273:8232–8239. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Remacle-Bonnet MM, Garrouste FL, Heller S,
André F, Marvaldi JL and Pommier GJ: Insulin-like growth factor-I
protects colon cancer cells from death factor-induced apoptosis by
potentiating tumor necrosis factor alpha-induced mitogen-activated
protein kinase and nuclear factor kappaB signaling pathways. Cancer
Res. 60:2007–2017. 2000.PubMed/NCBI
|
|
16
|
Wang J, Guo Y, Zhang BC, Chen ZT and Gao
JF: Induction of apoptosis and inhibition of cell migration and
tube-like formation by dihydroartemisinin in murine lymphatic
endothelial cells. Pharmacology. 80:207–218. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naing C, Mak JW, Aung K and Wong JY:
Efficacy and safety of dihydroartemisinin-piperaquine for treatment
of uncomplicated Plasmodium falciparum malaria in endemic
countries: Meta-analysis of randomised controlled studies. Trans R
Soc Trop Med Hyg. 107:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Du XX, Li YJ, Wu CL, Zhou JH, Han Y, Sui
H, Wei XL, Liu L, Huang P, Yuan HH, et al: Initiation of apoptosis,
cell cycle arrest and autophagy of esophageal cancer cells by
dihydroartemisinin. Biomed Pharmacother. 67:417–424. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu YY, Chen TS, Wang XP, Qu JL and Chen M:
The JNK inhibitor SP600125 enhances dihydroartemisinin-induced
apoptosis by accelerating Bax translocation into mitochondria in
human lung adenocarcinoma cells. FEBS Lett. 584:4019–4026. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao H, Gu H, Qu X, Sun J, Song B, Gao W,
Liu J and Shao Q: Involvement of the mitochondrial pathway and
Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human
breast cancer in vitro. Int J Mol Med. 31:213–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mu D, Chen W, Yu B, Zhang C, Zhang Y and
Qi H: Calcium and survivin are involved in the induction of
apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells.
Methods Find Exp Clin Pharmacol. 29:33–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mu D, Zhang W, Chu D, Liu T, Xie Y, Fu E
and Jin F: The role of calcium, P38 MAPK in
dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells.
Cancer Chemother Pharmacol. 61:639–645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Zhang BC, Guo Y, Chen ZT and Gao
JF: Inhibition of lymphangiogenesis, nodal and lung metastasis by
dihy-droartemisinin in mice bearing Lewis lung carcinoma. J Med
Coll PLA. 22:272–278. 2007. View Article : Google Scholar
|
|
24
|
Markman JL, Rekechenetskiy A, Holler E and
Ljubimova JY: Nanomedicine therapeutic approaches to overcome
cancer drug resistance. Adv Drug Deliv Rev. 65:1866–1879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu W and Kavanagh JJ: Anticancer therapy
targeting the apoptotic pathway. Lancet Oncol. 4:721–729. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han J, Lee JD, Tobias PS and Ulevitch RJ:
Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3
cells expressing CD14. J Biol Chem. 268:25009–25014.
1993.PubMed/NCBI
|
|
27
|
Han J, Lee JD, Bibbs L and Ulevitch RJ: A
MAP kinase targeted by endotoxin and hyperosmolarity in mammalian
cells. Science. 265:808–811. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
García-Cano J, Roche O, Cimas FJ,
Pascual-Serra R, Ortega-Muelas M, Fernández-Aroca DM and
Sánchez-Prieto R: p38MAPK and Chemotherapy: We always need to hear
both sides of the story. Front Cell Dev Biol. 4:692016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valladares A, Alvarez AM, Ventura JJ,
Roncero C, Benito M and Porras A: p38 mitogen-activated protein
kinase mediates tumor necrosis factor-alpha-induced apoptosis in
rat fetal brown adipocytes. Endocrinology. 141:4383–4395. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishii A, Furusho M and Bansal R: Sustained
activation of ERK1/2 MAPK in oligodendrocytes and schwann cells
enhances myelin growth and stimulates oligodendrocyte progenitor
expansion. J Neurosci. 33:175–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park MT, Choi JA, Kim MJ, Um HD, Bae S,
Kang CM, Cho CK, Kang S, Chung HY, Lee YS and Lee SJ: Suppression
of extracellular signal-related kinase and activation of p38 MAPK
are two critical events leading to caspase-8- and
mitochondria-mediated cell death in phytosphingosine-treated human
cancer cells. J Biol Chem. 278:50624–50634. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ozaki I, Tani E, Ikemoto H, Kitagawa H and
Fujikawa H: Activation of stress-activated protein kinase/c-Jun
NH2-terminal kinase and p38 kinase in calphostin C-induced
apoptosis requires caspase-3-like proteases but is dispensable for
cell death. J Biol Chem. 274:5310–5317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanagasabai R, Karthikeyan K, Vedam K,
Qien W, Zhu Q and Ilangovan G: Hsp27 protects adenocarcinoma cells
from UV-induced apoptosis by Akt and p21-dependent pathways of
survival. Mol Cancer Res. 8:1399–1412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park JG, Yuk Y, Rhim H, Yi SY and Yoo YS:
Role of p38 MAPK in the regulation of apoptosis signaling induced
by TNF-alpha in differentiated PC12 cells. J Biochem Mol Biol.
35:267–272. 2002.PubMed/NCBI
|
|
36
|
Petersen C, Svechnikov K, Fröysa B and
Söder O: The p38 MAPK pathway mediates interleukin-1-induced
Sertoli cell proliferation. Cytokine. 32:51–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang BC, Li Q, Ye J, et al: Role of
p38MAPK in mediating TNF-α-induced apoptosis of rat glioma cell
line C6. J Med Coll PLA. 18:308–311. 2003.
|
